

PRODUCT INFORMATION SHEET

Information Provided for Australian Veterinary Professionals Only

ilium TEMVET 90-DAY MULTIDOSE INJECTION



WHAT IS ILIUM TEMVET INJECTION?

- Indications:** For peri-operative and post-operative analgesia in cats. For post-operative analgesia and potentiation of the sedative effects of centrally acting agents in dogs. For the relief of post-operative pain in the horse only in conjunction with a sedative agent.
- Active Ingredient:** 300 µg/mL buprenorphine (as buprenorphine hydrochloride)
- Schedule:** S8 – Controlled drug. Possession without authority illegal.
- Physical Description:** Clear, colourless liquid

WHY CHOOSE ILIUM TEMVET INJECTION?


- ✓ 90-day in-use period after first broaching, when stored upright, helping reduce product wastage.
- ✓ Multi-species indications for peri-operative and post-operative analgesia in cats and post-operative analgesia in dogs and horses.
- ✓ Flexible administration by intramuscular (I.M.) or intravenous (I.V.) injection in cats and dogs, with intravenous (I.V.) administration in horses.
- ✓ Potent, long-acting opioid analgesic with limited sedative effect of its own at clinical doses.
- ✓ Suitable for premedication and sedation protocols, potentially enabling reductions in other centrally acting agents.
- ✓ Supplied in a 10 mL sterile multidose vial, with insulin-syringe administration recommended for accurate low-volume dosing in cats and dogs.
- ✓ Australian-made and Australian-owned.
- ✓ Conveniently available from your preferred wholesaler.

PRODUCT INFORMATION SHEET

Information Provided for Australian Veterinary Professionals Only

ilium
TEMVET

90-DAY MULTIDOSE INJECTION



HOW TO USE ILIUM TEMVET INJECTION?

Dose Rate: Due to the low volumes involved, care should be taken when administering this product to cats and dogs; an insulin syringe is recommended.

 CATS	Give 20 µg/kg body weight (0.067 mL/kg body weight) by intravenous (I.V.) or intramuscular (I.M.) injection. Administer the first dose 30 minutes preoperatively with premedication, and a second dose 1-2 hours later (at wound closure).
 DOGS	20 µg/kg body weight (0.067 mL/kg body weight) by intravenous (I.V.) or intramuscular (I.M.) injection given once preoperatively with premedication. For further pain relief, repeat if necessary, after five to six hours. Give 10 to 20 µg/kg body weight (0.034 to 0.067 mL/kg body weight) for the potentiation of sedation.
 HORSES	Give 5 - 10 µg per kg body weight (1.7 - 3.3 mL per 100 kg body weight) by intravenous (I.V.) injection, 5 minutes after administration of an I.V. sedative. The dose may be repeated if necessary, once, after not less than 1 - 2 hours and only after repeating the administration of an I.V. sedative.

Animals administered opioids with sedative and analgesic properties may show variable responses. Therefore, the response of individual animals should be monitored and subsequent doses should be adjusted accordingly. In some cases, repeat doses may fail to provide additional analgesia; in such cases, consideration should be given to using a suitable injectable nonsteroidal anti-inflammatory drug. Use of buprenorphine in conjunction with other centrally acting agents such as acepromazine, medetomidine or inhalation anaesthetics, may enable the dose of these agents to be reduced.

Administration Route: **Cats and dogs:** intramuscular (I.M.) or intravenous (I.V.). **Horses:** intravenous (I.V.) only.

Contraindications: Do not administer by the intrathecal or peridural route. Do not use pre-operatively for caesarean section.

Precautions: Buprenorphine is subject to a number of precautions and potential drug interactions. Please refer to the approved product label for full details.

Restraints: Do not use in horses that may be used for human consumption.

Side Effects: Mydriasis and signs of euphoria (excessive purring, pacing, rubbing) commonly occur in cats and will usually resolve within 24 hours. Salivation, bradycardia, hypothermia, agitation, dehydration and miosis can occur in dogs and, rarely, hypertension and tachycardia. When used to provide analgesia in horses, sedation is rarely seen, but may occur at dose rates higher than recommended. When used in conjunction with sedatives and tranquilisers, excitation is normally minimal, but ataxia may occasionally be marked. Colic is rarely reported. Buprenorphine may cause respiratory depression.

Storage Conditions: Store below 25 °C (air conditioning). Protect from light. Do not freeze. After first broaching the vial, store upright and use within 90 days. Discard the unused portion.

Please refer to the approved product label for full directions, precautions and safety information.

APVMA: 67612, 97461

www.troylab.com.au (+61) 2 8808 3600 sales@troylab.com.au

TROY